n-(3-(aminomethyl)benzyl)acetamidine has been researched along with Parkinson Disease in 2 studies
N-(3-(aminomethyl)benzyl)acetamidine: structure in first source
N-[3-(aminomethyl)benzyl]acetamidine : An aralkylamine that is Nbenzylacetamidine substituted at position 3 on the benzene ring by an aminomethyl group. An inhibitor of nitric oxide synthase.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brzozowski, MJ | 1 |
| Jenner, P | 1 |
| Rose, S | 1 |
| Gao, HM | 1 |
| Zhang, F | 1 |
| Zhou, H | 1 |
| Kam, W | 1 |
| Wilson, B | 1 |
| Hong, JS | 1 |
2 other studies available for n-(3-(aminomethyl)benzyl)acetamidine and Parkinson Disease
| Article | Year |
|---|---|
Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP(+)-induced neuronal toxicity.
Topics: Amidines; Animals; Antibodies, Monoclonal; Astrocytes; Benzylamines; Cell Count; Cells, Cultured; Do | 2015 |
Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Topics: alpha-Synuclein; Amidines; Animals; Animals, Genetically Modified; Benzylamines; Disease Models, Ani | 2011 |